New drug tested to protect fertility in women with rare tumors

NCT ID NCT07176689

Recruiting now Disease control Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study tests the drug nirogacestat in 50 premenopausal women with desmoid tumors (a type of non-cancerous but aggressive growth). The main goal is to see if the drug affects ovarian function, such as menstrual periods and hormone levels. Participants take nirogacestat orally, and researchers monitor for any temporary or lasting changes in fertility.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nirogacestat (oral tablet)
What this could lead to: If successful, this study could show that nirogacestat is safe for ovarian function, allowing younger women with desmoid tumors to preserve fertility while controlling their disease.
What could go wrong: This is a small, early-phase study with no placebo group, so results may not apply broadly. The drug may still cause ovarian toxicity or other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

desmoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AGGRESSIVE FIBROMATOSIS DESMOID TUMOR

Contacts and locations

Locations

Academisch Ziekenhuis Leiden
RECRUITING

Leiden, 2333 ZA, Netherlands
Cambridge University - Addenbrooke's Hospital
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Cliniques Universitaires Saint-Luc (CUSL)
RECRUITING

Brussels, 1200, Belgium
Fondazione IRCCS Istituto Nazionale dei Tumori Milano
RECRUITING

Milan, 20133, Italy
Hospital Fundacion Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
Hospital General Universitario Gregorio Maranon
RECRUITING

Madrid, 28007, Spain
Hospital Universitari i Politecnic La Fe de Valencia
RECRUITING

Valencia, 46026, Spain
Hospital Universitario 12 de Octubre
RECRUITING

Madrid, 28041, Spain
Hospital Universitario La Paz
RECRUITING

Madrid, 28046, Spain
Hospital Universitario Miguel Servet
RECRUITING

Zaragoza, 50009, Spain
Hospital de la Santa Creu i Sant Pau
RECRUITING

Barcelona, 08041, Spain
IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola
RECRUITING

Bologna, 40138, Italy
IRCCS Istituto Ortopedico Rizzoli di Bologna
RECRUITING

Bologna, 40138, Italy
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l.
RECRUITING

Meldola, Forli-Cesena, 47014, Italy
Institut Catala d'Oncologia
RECRUITING

Barcelona, 08907, Spain
Istituto Nazionale Tumori I.R.C.C.S- Fondazione G. Pascale
RECRUITING

Naples, 80131, Italy
La Fondazione e l'Istituto di Candiolo
RECRUITING

Candiolo, Torino, 10060, Italy
Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL)
RECRUITING

Amsterdam, 1066 CX, Netherlands
Policlinico Universitario Campus Bio-Medico
RECRUITING

Roma, 00128, Italy
The Christie NHS Foundation Trust
RECRUITING

Manchester, M20 4BX, United Kingdom
The Royal Marsden NHS Foundation Trust
RECRUITING

London, SW3 6JJ, United Kingdom
Universitaetsmedizin Mannheim
RECRUITING

Mannheim, 68167, Germany
University College London Hospital
RECRUITING

London, NW1 2PG, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.